Literature DB >> 21853394

Survival and quality of life after minimally invasive esophagectomy: a single-surgeon experience.

Abhishek Sundaram1, Juan C Geronimo, Brittany L Willer, Masato Hoshino, Zachary Torgersen, Arpad Juhasz, Tommy H Lee, Sumeet K Mittal.   

Abstract

BACKGROUND: Reports on quality of life (QOL) after minimally invasive esophagectomy (MIE) have been limited. This report compares perioperative outcomes, survival, and QOL after MIEs with open transthoracic esophagectomy (TTE) and open transhiatal esophagectomy (THE).
METHODS: After institutional review board approval, retrospective review of a prospectively maintained database identified patients who underwent esophageal resection for esophageal cancer at Creighton University between August 2003 and August 2010. Patients with preoperative stage 4 disease, emergent procedures, laparoscopic transhiatal esophagectomies, or esophagojeujunostomies were excluded from the study. The study patients were categorized as having undergone open TTE, open THE, or MIE. Overall survival (OS) was the interval between diagnosis and death or follow-up assessment. Disease-free survival (DFS) was the interval between surgery and recurrence, death, or follow-up assessment. For the patients who survived at least 1 year after surgery, QOL was assessed using European Organization for Research and Treatment of Cancer (EORTC-QLQ, version 3.0) and esophageal module (EORTC-QLQ OES 18) questionnaires.
RESULTS: The study criteria were satisfied by 104 patients. Lymph node harvest with MIE (median = 20) was similar to that with open TTEs (median = 19) and significantly higher (P < 0.001) than that with open THEs (median = 12). The percentage of patients requiring intraoperative blood transfusion in the MIE group (23.4%) was significantly lower (P < 0.001) than in the open TTE (73.1%) and THE (67.7%) groups. The volume of intraoperative blood product transfusion was significantly lower for the MIE patients (median = 0 ml) than for the open TTE (median = 700 ml) and THE (median = 700 ml) patients. The incidence of respiratory complications with MIEs (10.64%) was significantly lower than with open TTEs (34.61%) and THEs (32.26%). The groups did not differ significantly in terms of R0 resection rates, OS, DFS, or QOL.
CONCLUSIONS: MIEs offer a safe and viable alternative to open esophagectomies because they reduce the need and volume of intraoperative blood product transfusion and postoperative respiratory complications without compromising oncological clearance, survival, and QOL.

Entities:  

Mesh:

Year:  2011        PMID: 21853394     DOI: 10.1007/s00464-011-1850-7

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  26 in total

1.  Review of open and minimal access approaches to oesophagectomy for cancer.

Authors:  P M Safranek; J Cubitt; M I Booth; T C B Dehn
Journal:  Br J Surg       Date:  2010-10-04       Impact factor: 6.939

2.  Outcomes after esophagectomy: a ten-year prospective cohort.

Authors:  Stephen H Bailey; David A Bull; David H Harpole; Jeffrey J Rentz; Leigh A Neumayer; Theodore N Pappas; Jennifer Daley; William G Henderson; Barbara Krasnicka; Shukri F Khuri
Journal:  Ann Thorac Surg       Date:  2003-01       Impact factor: 4.330

3.  Applicability and feasibility of incorporating minimally invasive esophagectomy at a high volume center.

Authors:  Brittany L Willer; Sumeet K Mittal; Stephanie G Worrell; Seemal Mumtaz; Tommy H Lee
Journal:  J Gastrointest Surg       Date:  2010-06-08       Impact factor: 3.452

4.  Comparison of the outcomes between open and minimally invasive esophagectomy.

Authors:  Bernard M Smithers; David C Gotley; Ian Martin; Janine M Thomas
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

5.  Comparison of minimally invasive esophagectomy with transthoracic and transhiatal esophagectomy.

Authors:  N T Nguyen; D M Follette; B M Wolfe; P D Schneider; P Roberts; J E Goodnight
Journal:  Arch Surg       Date:  2000-08

6.  Comparative experience of open and minimally invasive esophagogastric resection.

Authors:  Rajeev Parameswaran; Darmarajah Veeramootoo; Rakesh Krishnadas; Martin Cooper; Richard Berrisford; Shahjehan Wajed
Journal:  World J Surg       Date:  2009-09       Impact factor: 3.352

7.  Predictors of postoperative quality of life after esophagectomy for cancer.

Authors:  Therese Djärv; Jane M Blazeby; Pernilla Lagergren
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

8.  Laparoscopic transhiatal esophagectomy with esophagogastroplasty.

Authors:  A L DePaula; K Hashiba; E A Ferreira; R A de Paula; E Grecco
Journal:  Surg Laparosc Endosc       Date:  1995-02

9.  Total number of resected lymph nodes predicts survival in esophageal cancer.

Authors:  Nasser K Altorki; Xi Kathy Zhou; Brendon Stiles; Jeffrey L Port; Subroto Paul; Paul C Lee; Madhu Mazumdar
Journal:  Ann Surg       Date:  2008-08       Impact factor: 12.969

10.  Minimally invasive esophagectomy: outcomes in 222 patients.

Authors:  James D Luketich; Miguel Alvelo-Rivera; Percival O Buenaventura; Neil A Christie; James S McCaughan; Virginia R Litle; Philip R Schauer; John M Close; Hiran C Fernando
Journal:  Ann Surg       Date:  2003-10       Impact factor: 12.969

View more
  32 in total

Review 1.  Combined thoracoscopic-laparoscopic esophagectomy versus open esophagectomy: a meta-analysis of outcomes.

Authors:  Wei Guo; Xiao Ma; Su Yang; Xiaoli Zhu; Wei Qin; Jiaqing Xiang; Toni Lerut; Hecheng Li
Journal:  Surg Endosc       Date:  2015-12-10       Impact factor: 4.584

Review 2.  Minimally invasive esophagectomy for esophageal cancer: an updated review.

Authors:  Masayuki Watanabe; Yoshifumi Baba; Yohei Nagai; Hideo Baba
Journal:  Surg Today       Date:  2012-08-28       Impact factor: 2.549

3.  The first randomised controlled trial on minimally invasive esophagectomy (MIE) and the ongoing quest for greater evidence.

Authors:  Marc M Dantoc; Michael R Cox; Guy D Eslick
Journal:  J Thorac Dis       Date:  2012-10       Impact factor: 2.895

4.  Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.

Authors:  Yuji Akiyama; Takeshi Iwaya; Fumitaka Endo; Takehiro Chiba; Takeshi Takahara; Koki Otsuka; Hiroyuki Nitta; Keisuke Koeda; Masaru Mizuno; Yusuke Kimura; Akira Sasaki
Journal:  Surg Endosc       Date:  2017-06-29       Impact factor: 4.584

Review 5.  Minimally invasive esophagectomy for dysplastic Barrett's esophagus.

Authors:  Sheraz R Markar; George Hanna
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

Review 6.  Total minimally invasive esophagectomy for esophageal cancer: approaches and outcomes.

Authors:  Danica N Giugliano; Adam C Berger; Ernest L Rosato; Francesco Palazzo
Journal:  Langenbecks Arch Surg       Date:  2016-07-11       Impact factor: 3.445

7.  Evolution in the Treatment of Esophageal Disease at a Single Academic Institution: 2004-2013.

Authors:  James P Dolan; Patrick J McLaren; Brian S Diggs; Paul H Schipper; Brandon H Tieu; Brett C Sheppard; Erin W Gilbert; Molly A Conroy; John G Hunter
Journal:  J Laparoendosc Adv Surg Tech A       Date:  2017-05-09       Impact factor: 1.878

8.  Oncological and surgical outcomes of minimally invasive versus open esophagectomy for esophageal squamous cell carcinoma: a matched-pair comparative study.

Authors:  Wenli Wang; Yongxin Zhou; Jing Feng; Yunqing Mei
Journal:  Int J Clin Exp Med       Date:  2015-09-15

9.  Thoracoscopic side-to-side esophagogastrostomy by use of linear stapler-a simplified technique facilitating a minimally invasive Ivor-Lewis operation.

Authors:  Tomoyuki Irino; Jon A Tsai; Jessica Ericson; Magnus Nilsson; Lars Lundell; Ioannis Rouvelas
Journal:  Langenbecks Arch Surg       Date:  2016-03-09       Impact factor: 3.445

Review 10.  [Evidence base for minimally invasive esophagectomy for esophageal cancer].

Authors:  F Benedix; S F Dalicho; P Stübs; D Schubert; C Bruns
Journal:  Chirurg       Date:  2014-08       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.